Janux Therapeutics, Inc. (JANX) Stock Forecast
JANX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.61 / 5 from 18 analysts
- Price target
- $36.24 average of analyst targets
- Upside to target
- +119.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.45
- 52-week range
- $12.18 – $34.74
JANX analyst ratings
18 analystsNumber of analysts at each rating.
JANX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
JANX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.49 | −$0.67 | −$0.04 | −$0.39 | −25.2% | 14 |
| Current fiscal year (2026) | −$1.73 | −$2.29 | −$0.97 | −$1.83 | +5.4% | 14 |
| Next fiscal year (2027) | −$2.62 | −$3.17 | −$2.06 | −$1.73 | −51.5% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
JANX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.4M | $0 | $35.0M | −35.8% | 13 |
| Current fiscal year (2026) | $29.4M | $14.0M | $77.2M | +194.2% | 14 |
| Next fiscal year (2027) | $8.1M | $0 | $26.7M | −72.5% | 14 |
JANX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
JANX revenue: reported and forecast
JANX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.50 | −$0.49 | −$0.49 | −$0.49 | −5.8% | 4 up · 7 down |
| Current fiscal year (2026) | −$1.76 | −$1.76 | −$1.73 | −$1.73 | −$1.73 | −1.8% | 7 up · 5 down |
| Next fiscal year (2027) | −$2.70 | −$2.64 | −$2.62 | −$2.62 | −$2.62 | −2.7% | 5 up · 7 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
JANX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; JANX beat in 9 of 12.
What analysts expect from JANX
18 analysts cover Janux Therapeutics; their consensus rating is strong buy (4.61 on a 1–5 scale, where 5 is a strong buy). The average price target is $36.24, 119.5% above the latest close of $16.51. Analysts expect earnings of −$1.73 per share for 2026, +5.4% from a year earlier. For 2027 the average estimate is −$2.62 per share on revenue of $8.1 million. Janux Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: JANX income statement, JANX key metrics, JANX chart. See the JANX stock overview for the latest quote and news.
JANX forecast FAQ
What is Janux Therapeutics's price target?
The average analyst price target for Janux Therapeutics is $36.24, 119.5% above the latest close of $16.51.
Is Janux Therapeutics a buy, hold or sell?
Of 18 analysts covering Janux Therapeutics, 14 rate it a strong buy, 2 a buy, 1 a hold, 1 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Janux Therapeutics's EPS forecast?
Analysts forecast −$1.73 per share for 2026 (range −$2.29 to −$0.97); for 2027 the estimate is −$2.62.
What is Janux Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $29.4 million, growth of 194.2%; for 2027 it is $8.1 million.
When does Janux Therapeutics report earnings?
Janux Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.45.
Does Janux Therapeutics usually beat earnings estimates?
Janux Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.